Pour une meilleure utilisation, nous vous conseillons d’activer Javascript dans votre navigateur.

Z-LEHD-FMK (Caspase-9 Inhibitor)

Name: Z-LEHD-FMK (Caspase-9 Inhibitor)
SKU: ABIN2691061
Availability: InStock

Func, CC, BR, InhA Cell-permeable Z-LEHD-fluoromethylketone

(2 références)

N° du produit ABIN2691061

257,23 €

Plus frais de livraison 40,00 € et TVA

1 mg

Destination: France

Envoi sous 12 à 15 jours ouvrables

Aperçu rapide pour Z-LEHD-FMK (Caspase-9 Inhibitor) (ABIN2691061)

Application

Functional Studies (Func), Cell Culture (CC), Blocking Reagent (BR), Inhibition Assay (InhA)

Chemical Name

Z-LEHD-fluoromethylketone

Perméabilité

Cell-permeable

Fonction

A caspase-9 inhibitor

Séquence

Z-Leu-Glu(OMe)-His-Asp(OMe)-CH2F (TFA salt), Z-LEHD-FMK

Attributs du produit

Members of the caspase family play key roles in inflammation and mammalian apoptosis. Z-LEHD-FMK is an irreversible and cell permeable inhibitor of caspase-9. The peptide is O-methylated in the P1 position on aspartic acid providing enhanced stability and increased cell permeability. Z-LEHD-FMK can be used to inhibit primarily caspase-9 activity and to study events downsteam of caspase-9 activation. Z-LEHD-FMK has been reported to have a molecular weight of 804 Daltons. Flow cytometric analysis of apoptosis in Jurkat cells. Jurkat cells (Human T-cell leukemia, ATCC TIB-152) were preincubated with the following: no inhibitor (top and bottom left panels), 20 μM Z-LEHD-FMK (top and bottom center panels) or 20 μM control inhibitor, Z-FA-FMK (top and bottom right panels) for 30 min, and then either left untreated (bottom row) or treated with 4 μM of campthothecin for 3 hr (top row). Following incubation, cells were collected and stained with PE-Annexin V (Cat. No. 559763) to identify cells undergoing apoptosis. The results indicate that in campthothecin treated cells approximately 42 % of the cells were induced to undergo apoptosis and the use of the caspase-9 inhibitor Z-LEHD-FMK reduced the level of apoptosis to half of that level observed in treated controls. Cells treated with Z-FA-FMK (Cat. No. 550411) showed similar results to the treated cells without inhibitor, indicating that the control inhibitor did not attenuate apoptosis.

Purification

Purified

Solubility

DMSO
Geldanamycin- FITC
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Radicicol
Inh 12772-57-5

Geldanamycin- Biotin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Herbimycin A
Inh 70563-58-5 [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

17-GMB-APA-GA
Inh [(3R,5S,6R,7S,10S,11S)-21-[3-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]propylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

TEMPO
Inh 2564-83-2 2,2,6,6-Tetramethylpiperidine 1-oxyl, 2,2,6,6-Tetramethyl-1-piperidinyloxy, free radical, (2,2,6,6-Tetramethyl-1-piperidinyl)oxidanyl, 1,1,5,5-tetramethylpentamethylene nitroxide, 2,2,6,6-Tetramethylpiperidine-1-oxyl

Triacsin C
Inh 76896-80-5 (3E)-1-Oxo-3-[(2E,4E,7E)-2,4,7-undecatrien-1-ylidene]triazane

TPCK
Inh 402-71-1 N-(4-Chloro-3-oxo-1-phenyl-2-butanyl)-4-methylbenzenesulfonamide

Staurosporine
Inh 62996-74-1 (2S,3R,4R,6R)-3-Methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one

Commentaires

BD Pharmingen™ Z-LEHD-FMK, Caspase-9 Inhibitor – Purified
Members of the caspase family play key roles in inflammation and mammalian apoptosis. Z-LEHD-FMK is an irreversible and cell permeable inhibitor of caspase-9. The peptide is O-methylated in the P1 position on aspartic acid providing enhanced stability and increased cell permeability. Z-LEHD-FMK can be used to inhibit primarily caspase-9 activity and to study events downsteam of caspase-9 activation. Z-LEHD-FMK has been reported to have a molecular weight of 804 Daltons.

Restrictions

For Research Use only
Format

Lyophilized

Reconstitution

Reconstitute the inhibitor in DMSO before use. The reconstituted inhibitor may be stored in small aliquots at -20 °C.

Stock

-20 °C

Stockage commentaire

Avoid multiple freeze-thaws of product. Z-LEHD-FMK, Caspase-9 Inhibitor is provided as a lyophilized powder. Store the lyophilized inhibitor at -20°C. Reconstitute the inhibitor in DMSO before use. The reconstituted inhibitor may be stored in small aliquots at -20°C.
Maccarrone, Lorenzon, Bari, Melino, Finazzi-Agro: "Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors." dans: The Journal of biological chemistry, Vol. 275, Issue 41, pp. 31938-45, (2000) (PubMed).

Thornberry, Lazebnik: "Caspases: enemies within." dans: Science (New York, N.Y.), Vol. 281, Issue 5381, pp. 1312-6, (1998) (PubMed).
Poids moléculaire

804 Da